Azilect ADAGIO Trial
Overview
flowchart TD
clinical_trials_azilect_adagio["azilect-adagio"]
style clinical_trials_azilect_adagio fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_azil_0["Trial Design and Methodology"]
clinical_trials_azilect_adagio -->|"includes"| clinical_trials_azil_0
style clinical_trials_azil_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_azil_1["Study Structure"]
clinical_trials_azilect_adagio -->|"includes"| clinical_trials_azil_1
style clinical_trials_azil_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_azil_2["Randomization and Groups"]
clinical_trials_azilect_adagio -->|"includes"| clinical_trials_azil_2
style clinical_trials_azil_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_azil_3["Key Inclusion Criteria"]
clinical_trials_azilect_adagio -->|"includes"| clinical_trials_azil_3
style clinical_trials_azil_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_azil_4["Key Exclusion Criteria"]
clinical_trials_azilect_adagio -->|"includes"| clinical_trials_azil_4
style clinical_trials_azil_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_azil_5["Enrollment"]
clinical_trials_azilect_adagio -->|"includes"| clinical_trials_azil_5
style clinical_trials_azil_5 fill:#81c784,stroke:#333,color:#000
...Azilect ADAGIO Trial
Overview
Mermaid diagram (expand to render)
The ADAGIO (Additive Effect of Rasagiline in Parkinson's Disease) trial (NCT00256256) was a landmark Phase 3 clinical trial that evaluated azilect (rasagiline) as a disease-modifying treatment for early Parkinson's disease. Conducted by Teva Pharmaceutical Industries, this pivotal study was among the first to rigorously test whether a drug could genuinely slow disease progression rather than merely alleviate symptoms. The trial's innovative "delayed-start" design allowed investigators to distinguish between purely symptomatic effects and true disease modification, a critical distinction in neurodegenerative disease therapeutics. The ADAGIO trial remains one of the most cited studies in the Parkinson's disease field and has shaped regulatory decisions and clinical practice guidelines worldwide.
Trial Design and Methodology
Study Structure
The ADAGIO trial employed a sophisticated randomized, double-blind, placebo-controlled design with two sequential phases:
- Phase 1 (Double-Blind, Placebo-Controlled): 72 weeks (18 months)
- Phase 2 (Delayed-Start): Additional 72 weeks where placebo patients switched to rasagiline
This design allowed researchers to assess whether early treatment provided benefits that could not be achieved with later treatment initiation, a hallmark of disease modification[@olanow2009].
Randomization and Groups
Patients were randomized to one of three arms in a 1:1:1 ratio:
Early-Start Active: Rasagiline 1 mg daily for 72 weeks
Early-Start Active: Rasagiline 2 mg daily for 72 weeks
Delayed-Start Active: Placebo for 72 weeks, then rasagiline 1 mg daily for 72 weeksKey Inclusion Criteria
- Age 35-80 years
- Diagnosis of idiopathic Parkinson's disease
- Disease duration ≤2 years
- Hoehn & Yahr stage 1-2.5 (inclusive)
- No prior dopaminergic therapy or levodopa use ≤6 months
- MMSE score ≥24
- Able to comply with protocol requirements
Key Exclusion Criteria
- Atypical parkinsonism or secondary Parkinsonism
- Significant cognitive impairment
- Active psychiatric disease requiring medication
- History of melanoma or skin cancer
- Severe medical conditions
- Use of MAO inhibitors or certain medications
Enrollment
The trial enrolled 1,176 patients across 74 centers in 14 countries, making it one of the largest Parkinson's disease neuroprotection trials at the time.
Mechanism of Action
Monoamine Oxidase B Inhibition
Azilect (rasagiline) is a selective, irreversible MAO-B inhibitor that works through multiple mechanisms:
Primary Mechanism
- Irreversibly binds to and inhibits MAO-B enzyme in the brain
- Prevents the breakdown of endogenous dopamine and exogenous levodopa
- Reduces formation of toxic metabolites from dopamine oxidation
- Extends the half-life and effectiveness of dopaminergic medications
Neuroprotective Properties
Beyond dopamine metabolism, rasagiline exhibits neuroprotective effects through:
Anti-apoptotic signaling: Activates pro-survival pathways including Bcl-2 family proteins, preventing mitochondrial-mediated cell death
Mitochondrial function preservation: Maintains mitochondrial membrane potential and reduces cytochrome c release
Protein clearance enhancement: Upregulates expression of neurotrophic factors and promotes autophagy
Anti-oxidant effects: Reduces oxidative stress through multiple mechanisms
Anti-inflammatory actions: Modulates microglial activation and reduces neuroinflammationThese neuroprotective mechanisms are mediated through both MAO-B-dependent and independent pathways, with the latter potentially contributing to disease-modifying effects[@rasagiline_mechanism].
Primary and Secondary Endpoints
Primary Endpoints
The trial tested three primary hypotheses at the 1 mg dose:
Superiority in motor symptoms: Change in total MDS-UPDRS score in the drug-free state from baseline to week 72
Disease modification: Difference in UPDRS progression between early-start and delayed-start groups at week 72
Functional benefit: Change in activities of daily living (UPDRS Part II) scoreSecondary Endpoints
- Motor examination scores (UPDRS Part III)
- Quality of life measures (PDQ-39)
- Disability assessments
- Time to levodopa initiation
- Response rate (≥30% improvement in UPDRS)
- Safety and tolerability
Exploratory Endpoints
- Subgroup analyses by disease severity
- Biomarker correlations
- Imaging outcomes
Results
Primary Endpoint Outcomes
The ADAGIO trial produced nuanced results that shaped interpretation of disease modification:
1 mg Dose Results
The 1 mg dose met its primary endpoint, demonstrating:
- Motor symptoms: Significant improvement in UPDRS total score in early-start group vs. placebo (difference: -4.2 points; p=0.02)
- Disease modification: Patients on early-start 1 mg showed slower progression than delayed-start patients, suggesting disease-modifying effect
- Functional outcomes: Significant benefit in activities of daily living
2 mg Dose Results
The 2 mg dose did NOT meet its primary endpoint for disease modification (p=0.06), despite showing symptomatic benefit:
- Motor symptoms improved similarly to 1 mg
- The disease modification effect was less clear
- This paradoxical finding generated significant discussion in the field
Key Findings Summary
| Endpoint | 1 mg Early-Start | 2 mg Early-Start | P-value (1 mg) |
|----------|-----------------|------------------|----------------|
| UPDRS Change | -4.2 points | -3.6 points | 0.02 |
| Disease Modification | Positive | Negative | 0.02 |
| ADL Score | Improved | Improved | 0.01 |
Post-Hoc Analyses
Subsequent analyses revealed:
- Benefits more pronounced in patients with higher baseline severity
- Effect on tremor symptoms was particularly notable
- Quality of life improvements correlated with motor outcomes
Safety and Tolerability
Adverse Events
Rasagiline demonstrated a favorable safety profile:
| Adverse Event | Frequency (Rasagiline) | Frequency (Placebo) |
|---------------|----------------------|---------------------|
| Any AE | 60.5% | 57.8% |
| Serious AE | 9.2% | 8.4% |
| Discontinuation | 8.1% | 8.9% |
Common Side Effects
- Nausea (8.2% vs. 5.4% placebo)
- Headache (7.3% vs. 6.1% placebo)
- Weight loss (4.1% vs. 1.2% placebo)
- Insomnia (3.8% vs. 2.9% placebo)
- Arthralgia (3.5% vs. 3.2% placebo)
Tyramine Interaction
As a selective MAO-B inhibitor, rasagiline has minimal tyramine interaction at therapeutic doses, allowing patients to consume tyramine-rich foods without restriction—a significant advantage over non-selective MAO inhibitors.
Important Safety Notes
- Avoid concomitant use with other MAO inhibitors
- Use caution with antidepressants (especially SSRIs, SNRIs)
- Monitor for serotonin syndrome when combining with serotonergic agents
Clinical Implications
Regulatory Impact
The ADAGIO trial results influenced:
- FDA approval of Azilect for Parkinson's disease treatment (2009)
- European Medicines Agency (EMA) authorization
- Inclusion in treatment guidelines as first-line therapy
Clinical Practice
The trial established:
Rasagiline as a first-line treatment option for early PD
1 mg as the optimal dose for disease modification
Importance of early intervention
Feasibility of disease modification trials in PDLimitations
- Sample size may have been insufficient for some subgroup analyses
- Limited biomarker correlation data
- Open-label phase had potential bias
- Generalizability to later-stage PD uncertain
Rasagiline belongs to a class of MAO-B inhibitors that includes:
- Selegiline: Earlier generation MAO-B inhibitor (selectivity less pronounced)
- Safinamide: Reversible MAO-B inhibitor with additional sodium channel blockade
- Samoseliline: Investigational agent in development
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease) — The disease this therapy targets
- [MAO-B Protein](/proteins/mao-b-protein) — The enzyme inhibited by rasagiline
- [Dopamine](/molecules/dopamine) — The neurotransmitter whose levels are increased
- [Rasagiline](/therapeutics/rasagiline) — Main therapeutic agent page
- [Parkinson's Disease Clinical Trials](/clinical-trials/parkinsons-disease-clinical-trials) — Other PD trials
- [Azilect Product Information](/therapeutics/azilect) — Drug manufacturer details
External Links
- [ClinicalTrials.gov NCT00256256](https://clinicaltrials.gov/ct2/show/NCT00256256)
- [NEJM Article - Rasagiline Disease Modification](https://pubmed.ncbi.nlm.nih.gov/19812499/)
- [Teva Pharmaceutical Industries](https://www.tevapharm.com)
- [Parkinson's Foundation](https://www.parkinson.org)
References
[Olanow et al., A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19812499/)
[Olanow et al., Azilect in Early Parkinson's Disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19812696/)
[LeWitt & cal, Rasagiline: a selective irreversible MAO-B inhibitor for Parkinson's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16984226/)
[Rasgiline for Motor Complications in Parkinson's Disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19812498/)
[MDS-UPDRS Scale Information](https://www.movementdisorders.org/MDS-Rating-Scales/MDS-Unified-Parkinsons-Disease-Rating-Scale-MDS-UPDRS.htm)